ArticleSkin health and disease2026
Narrowband ultraviolet B and psoralen plus ultraviolet A phototherapy treatment for mycosis fungoides: a 17-year retrospective cohort study in a university teaching hospital, 2007-24.
Article in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma. MF is typically managed with narrowband ultraviolet B (NB-UVB) or psoralen plus ultraviolet A (PUVA) phototherapy. However, comparative data on their efficacy remain limited. Objectives: To evaluate the treatment outcomes of NB-UVB and PUVA in MF and to identify clinical and demographic predictors of response. Methods: This was a retrospective cohort study of 33 patients with biopsy-proven MF treated with NB-UVB or PUVA between 2007 and 2024 in the dermatology department at the Sandwell and West Birmingham Hospitals National Health Service Trust. Statistical analysis was performed using Microsoft Excel version 2023 and R version 2023.03.1 + 446. Results: Of the 33 patients (median age 58 years), 26 (79%) received NB-UVB, 5 (15%) PUVA and 2 (6%) both. Complete remission was achieved in 15 cases (45%) and partial remission in 15 (45%), with 3 (9%) showing no response. Patients with hypopigmented MF had significantly better outcomes than those with hyperpigmented MF ( Conclusions: NB-UVB and PUVA are effective and well tolerated for the treatment of MF. Hypopigmented variants and -early-disease stage predicted better outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.